| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on August 28, 2003; DOI 10.1182/blood-2003-04-1255.
Submitted April 22, 2003
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA; Department of Pathology, University of Tennessee School of Medicine, Memphis, TN, USA * Corresponding author; email: terrence.geiger{at}stjude.org.
Recent pre-clinical and clinical trials have demonstrated the therapeutic potential of T lymphocytes redirected with genetically engineered T-cell receptor (TCR) surrogates against infected, cancerous, or autoreactive cells. These surrogate TCRs link a ligand-recognition domain to signaling regions from the TCR. We previously compared the function of surrogate TCRs that include TCR or TCR and CD28 signaling regions. We found that primary murine T cells modified to specifically target Kb-restricted CD8+ T cells using either Kb-
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||